鹭燕医药
(002788)
| 流通市值：31.84亿 | | | 总市值：32.40亿 |
| 流通股本：3.82亿 | | | 总股本：3.89亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,400,082,294.54 | 5,173,756,306.59 | 20,470,766,084.92 | 15,413,532,406.63 |
| 营业收入 | 10,400,082,294.54 | 5,173,756,306.59 | 20,470,766,084.92 | 15,413,532,406.63 |
| 二、营业总成本 | 10,181,523,653.52 | 5,068,450,829.67 | 20,001,054,777.2 | 15,050,903,211.4 |
| 营业成本 | 9,661,434,491.75 | 4,811,720,633.33 | 18,946,245,237.9 | 14,281,433,662.95 |
| 税金及附加 | 26,614,089.57 | 11,144,101.18 | 48,156,149.95 | 34,074,119.91 |
| 销售费用 | 234,193,210.5 | 116,719,960.36 | 467,938,219.31 | 341,694,741.81 |
| 管理费用 | 160,132,453.54 | 78,463,832.55 | 321,236,419.1 | 234,673,637.54 |
| 研发费用 | 2,835,547.03 | 1,365,879.98 | 5,845,992.92 | 3,635,551.77 |
| 财务费用 | 96,313,861.13 | 49,036,422.27 | 211,632,758.02 | 155,391,497.42 |
| 其中:利息费用 | 94,510,361.13 | 47,983,622 | 206,683,877.39 | 152,951,908.08 |
| 其中:利息收入 | 1,707,913.41 | 184,096.79 | 3,837,401.35 | 3,012,156.36 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -9,374,070.99 | -5,056,306.36 | -18,730,952.34 | -12,979,289.94 |
| 资产处置收益 | 98,166.8 | 1,179.75 | 172,333.63 | 67,986.37 |
| 资产减值损失(新) | -1,205,140.97 | -120,427.13 | -1,874,339.26 | -289,948.89 |
| 信用减值损失(新) | -6,957,339.51 | -8,760,515.38 | -813,088.15 | -17,520,254 |
| 其他收益 | 1,995,000.02 | 1,231,027.71 | 9,632,306.15 | 5,285,128.14 |
| 四、营业利润 | 203,115,256.37 | 92,600,435.51 | 458,097,567.75 | 337,192,816.91 |
| 加:营业外收入 | 1,695,757.15 | 927,432.07 | 4,524,078.32 | 1,361,343.06 |
| 减:营业外支出 | 1,484,180.35 | 982,792.23 | 9,348,475.99 | 4,749,735.65 |
| 五、利润总额 | 203,326,833.17 | 92,545,075.35 | 453,273,170.08 | 333,804,424.32 |
| 减:所得税费用 | 49,887,206.91 | 22,789,976.94 | 105,575,203.58 | 75,903,320.59 |
| 六、净利润 | 153,439,626.26 | 69,755,098.41 | 347,697,966.5 | 257,901,103.73 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 153,439,626.26 | 69,755,098.41 | 347,697,966.5 | 257,901,103.73 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 154,529,883.5 | 71,323,645.12 | 345,644,716.96 | 257,346,811.41 |
| 少数股东损益 | -1,090,257.24 | -1,568,546.71 | 2,053,249.54 | 554,292.32 |
| 扣除非经常损益后的净利润 | 153,471,103.05 | 70,886,100.17 | 347,203,700.32 | 259,407,296.44 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.4 | 0.18 | 0.89 | 0.66 |
| (二)稀释每股收益 | - | - | - | 0.66 |
| 八、其他综合收益 | -229,551.12 | 23,339.27 | 397,854.6 | -67,892.15 |
| 归属于母公司股东的其他综合收益 | -229,551.12 | 23,339.27 | 397,854.6 | -67,892.15 |
| 九、综合收益总额 | 153,210,075.14 | 69,778,437.68 | 348,095,821.1 | 257,833,211.58 |
| 归属于母公司股东的综合收益总额 | 154,300,332.38 | 71,346,984.39 | 346,042,571.56 | 257,278,919.26 |
| 归属于少数股东的综合收益总额 | -1,090,257.24 | -1,568,546.71 | 2,053,249.54 | 554,292.32 |
| 公告日期 | 2025-08-26 | 2025-04-22 | 2025-04-22 | 2024-10-22 |
| 审计意见(境内) | | | 标准无保留意见 | |